Valproate in the treatment of epilepsy in girls and women of childbearing potential

Epilepsia

Volumn 56, Issue 7, 2015, Pages 1006-1019

  Tomson, Torbjörn ^a   Marson, Anthony ^b,c   Boon, Paul ^d   Canevini, Maria Paola ^e   Covanis, Athanasios ^f   Gaily, Eija ^g   Kälviäinen, Reetta ^h,i   Trinka, Eugen ^j,k,l  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF MILAN   (Italy)

^f AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^g UNIVERSITY OF HELSINKI   (Finland)

^h UNIVERSITY OF EASTERN FINLAND   (Finland)

ⁱ KUOPIO UNIVERSITY HOSPITAL   (Finland)

^j PARACELSUS MEDICAL UNIVERSITY   (Austria)

^k UNIVERSITY OF SALZBURG   (Austria)

^l UNIVERSITY FOR HEALTH SCIENCES   (Austria)

more..

Author keywords

Anticonvulsants; Epilepsy; Pregnancy; Teratogenicity; Valproate; Valproic acid

Indexed keywords

VALPROIC ACID; ANTICONVULSIVE AGENT;

ABSENCE SEIZURE; ARTICLE; BEHAVIOR; COGNITIVE DEVELOPMENT; DISEASE CONTROL; DRUG EFFICACY; EPILEPSY; FEMALE; FETUS RISK; GENERALIZED EPILEPSY; HUMAN; IDIOPATHIC DISEASE; MONOTHERAPY; PREGNANCY; PREGNANT WOMAN; PRIMARY GENERALIZED TONIC CLONIC SEIZURE; PRIORITY JOURNAL; RISK ASSESSMENT; SEIZURE; TERATOGENICITY; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; UNPLANNED PREGNANCY; AGE; CHEMICALLY INDUCED; PRENATAL EXPOSURE; PREVENTION AND CONTROL;

AGE FACTORS; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84936845969     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13021     Document Type: Article

References (63)

1. European Medicines Agency. Assessment Report. Procedure Under Article 31 of Directive 2001/83/EC Resulting from Pharmacovigilance Data. 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/Valproate-and-related-substances-31/Recommendation-provided-by-Pharmacovigilance-Risk-Assessment-Committee/WC500177352.pdf. Accessed April, 2015.
2. Nau H,. Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol 1985; 80: 243-250.
3. Mawhinney E, Campbell J, Craig J, et al., Valproate and the risk of congenital malformations: is formulation and dosage regime important? Seizure 2012; 21: 215-218.
4. Tomson T, Battino D, Bonizzoni E, et al., Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10: 609-617.
5. Meador KJ, Baker GA, Browning N, et al., Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013; 12: 244-252.
6. Meador K, Reynolds MW, Crean S, et al., Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008; 81: 1-13.
7. Hernandez-Diaz S, Smith CR, Shen A, et al., Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78: 1692-1699.
8. Campbell E, Kennedy F, Russell A, et al., Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014; 85: 1029-1034.
9. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE,. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 2014; 261: 579-588.
10. Tomson T, Battino D,. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012; 11: 803-813.
11. Mawhinney E, Craig J, Morrow J, et al., Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013; 80: 400-405.
12. Hunt S, Russell A, Smithson WH, et al., UK Epilepsy and Pregnancy Register. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008; 71: 272-276.
13. Samrén EB, van Duijn CM, Koch S, et al., Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981-990.
14. Samrén EB, van Duijn CM, Christiaens GC, et al., Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739-746.
15. Kaneko S, Battino D, Andermann E, et al., Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33: 145-158.
16. Artama M, Auvinen A, Raudaskoski T, et al., Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005; 64: 1874-1878.
17. Bromley R, Weston J, Adab N, et al., Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014;Art. No.: CD010236.
18. Baker GA, Bromley RL, Briggs M, et al., IQ at 6 years following in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015; 84: 382-390.
19. Shallcross R, Bromey RL, Cheyne CP, et al., In utero exposure to levetiracetam vs valproate. Neurology 2014; 82: 213-221.
20. Cohen MJ, Meador KJ, Browning N, et al., Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy Behav 2011; 22: 240-246.
21. Cohen MJ, Meador KJ, Browning N, et al., Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav 2013; 29: 308-315.
22. Christensen J, Gronborg TK, Sorensen MJ, et al., Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013; 309: 1696-1703.
23. Posner EB, Mohamed KK, Marson AG,. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2005;Art. No.: CD003032.
24. Coppola G, Auricchio G, Federico R, et al., Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia 2004; 45: 1049-1053.
25. Glauser TA, Cnaan A, Shinnar S, et al., Ethosuximide, valproic acid and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362: 790-799.
26. Marson AG, Al-Kharusi AM, Alwaidh M, et al., The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblended randomised controlled trial. Lancet 2007; 369: 1016-1026.
27. Bonnett LJ, Tudur Smith C, et al., Time to 12-month remission and treatment failure for generalised and unclassified epilepsy. J Neurol Neurosurg Psychiatry 2014; 85: 603-610.
28. Fattore C, Boniver C, Capovilla G, et al., A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 2011; 52: 802-809.
29. Marson AG, Williamson PR, Hutton JL, et al., Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev 2000;Art. No.: CD001030.
30. Nolan SJ, Marson AG, Pulman J, et al., Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst Rev 2013;Art. No.: CD001769.
31. Tudur Smith C, Marson AG, Chadwick DW, et al., Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007; 8: 34.
32. Trinka E, Marson AG, Van Paesschen W, et al., KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013; 84: 1138-1147.
33. Park KM, Kim SH, Nho SK, et al., A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy. J Clin Neurosci 2013; 20: 1079-1082.
34. Levisohn PM, Holland KD,. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav 2007; 10: 547-552.
35. Noachtar S, Andermann E, Meyvisch P, et al., Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70: 607-616.
36. Covanis A, Gupta AK, Jeavons PM,. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982; 23: 693-720.
37. Bourgeois B, Beaumanoir A, Blajev B, et al., Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987; 28 (Suppl. 2): S8-S11.
38. Nicolson A, Appleton RE, Chadwick DW, et al., The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004; 75: 75-79.
39. Genton P,. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000; 22: 75-80.
40. Hesdorffer DC, Tomson T, Benn E, et al., Combined analysis of risk factors for SUDEP. Epilepsia 2011; 52: 1150-1159.
41. Nilsson L, Tomson T, Farahmand BY, et al., Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 1997; 38: 1062-1068.
42. Tomson T, Beghi E, Sundqvist A, Johannessen SI,. Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res 2004; 60: 1-16.
43. Granbichler CA, Oberaigner W, Kuchukhidze G, et al., Cause-specific mortality in adult epilepsy patients from Tyrol, Austria: hospital-based study. J Neurol 2015; 262: 126-133.
44. Trinka E, Bauer G, Oberaigner W, et al., Cause-specific mortality among patients with epilepsy: results from a 30-year cohort study. Epilepsia 2013; 54: 495-501.
45. Cummings C, Stewart M, Stevenson M, et al., Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011; 96: 643-647.
46. Grosso S, Balestri M, Di Bartolo RM, et al., Oxcarbazepine and atypical evolution of benign idiopathic focal epilepsy of childhood. Eur J Neurol 2006; 13: 1142-1145.
47. Wheless JW, Clarke DF, Arzimanoglou A, et al., Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007; 9: 353-412.
48. Berg AT, Berkovic SF, Brodie MJ, et al., Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51: 676-685.
49. Callenbach PM, Bouma PA, Geerts AT, et al., Long-term outcome of childhood absence epilepsy: Dutch Study of Epilepsy in Childhood. Epilepsy Res 2009; 83: 249-256.
50. Trinka E, Baumgartner S, Unterberger I, et al., Long-term prognosis for childhood and juvenile absence epilepsy. J Neurol 2004; 251: 1235-1241.
51. Covanis A, Skiadas K, Loli N, et al., Absence epilepsy: early prognostic signs. Seizure 1992; 1: 281-289.
52. Caraballo RH, Flesler S, Pasteris MC, et al., Myoclonic epilepsy in infancy: an electroclinical study and long-term follow-up of 38 patients. Epilepsia 2013; 54: 1605-1612.
53. Wallace S,. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998; 29: 147-154.
54. Genton P, Bureau M,. Epilepsy with myoclonic absences. CNS Drugs 2006; 20: 911-916.
55. Oguni H, Tanaka T, Hayashi K,. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002; 33: 122-132.
56. Liukkonen E, Kantola-Sorsa E, Paetau R, et al., Long-term outcome of 32 children with encephalopathy with status epilepticus during sleep, or ESES syndrome. Epilepsia 2010; 51: 2023-2032.
57. Shahwan A, Farrell M, Delanty N,. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005; 4: 239-248.
58. Avula S, Parikh S, Demarest S, et al., Treatment of mitochondrial disorders. Curr Treat Options Neurol 2014; 16: 292.
59. Chiron C, Dulac O,. The pharmacologic treatment of Dravet syndrome. Epilepsia 2011; 52 (Suppl. 2): 72-75.
60. Chiron C, Marchand MC, Tran A, et al., Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356: 1638-1642.
61. Trinka E, Dilitz E, Unterberger I, et al., Non convulsive status epilepticus after replacement of valproate with lamotrigine. J Neurol 2002; 249: 1417-1422.
62. MRC Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 1991; 337: 1175-1180.
63. MRC Antiepileptic Drug Withdrawal Study Group. Prognostic index for recurrence of seizures after remission of epilepsy. BMJ 1993; 306: 1374-1378.